He cracked malaria’s genome in Mali. Now he’s advising the UN

When Abdoulaye Djimdé lastly had a second to speak, he was in a resort room in Nairobi, Kenya, his web connection flickering, cameras off to save lots of bandwidth. He had one other assembly to get to. He all the time has one other assembly to get to.

Djimdé was appointed in March to the United Nations Secretary-General’s Scientific Advisory Board, a physique that advises on science and expertise. It is, he says, an area the place African scientific voices are wanted.

The board offers unbiased, evidence-based steering on science and expertise for sustainable growth and policymaking. Djimdé’s appointment brings an African viewpoint, significantly on infectious ailments, genomic surveillance, and analysis capability.

“We African scientists research malaria because we live the problem. It is a very important advisory role—the committee tackles important science issues in terms of innovation, directions that the world’s science is taking, and discusses how these new directions and innovations would impact society at large,” Djimdé says. “Having African voices represented in those discussions would bring into consideration the perspective of the African continent.”

That perspective has been cast over a long time of fieldwork. As a professor of parasitology and mycology at the University of Sciences, Techniques, and Technologies of Bamako—in Mali, one among the world’s most malaria-burdened nations—Djimdé and his lab sit at the intersection of subject science and international well being coverage. His crew assessments drug candidates towards parasites collected immediately from sufferers reasonably than strains which have spent a long time adapting to laboratory situations.

“In the Global North, colleagues tend to work with what I call pet parasites—parasites that have been in the lab for 30 years, adapted to lab conditions, grown and regrown so many times that their features are sometimes different from what you find in patients today,” Djimdé says.

Working with present subject isolates, his crew reaches conclusions about drug candidates that diverge sharply from findings made in labs that use solely laboratory fashions. For instance, a research Djimdé’s lab printed not too long ago compares how well 14 antimalarial drugs performed towards Plasmodium falciparum, the deadliest malaria parasite unfold by mosquitoes (J. Antimicrob. Chemother.-Antimicrob. Resist. 2026, DOI: 10.1093/jacamr/dlag015). The crew seen vital variations in drug responses and linked these to every of three websites the parasites had been collected from. The variability the researchers discovered in drug resistance might inform therapy methods in every area, the researchers report.

That give attention to subject analysis had outlined Djimdé’s work from the starting. His doctoral analysis at the University of Maryland, Baltimore, led him to research why chloroquine, the frontline drug towards malaria for many years, had stopped working in sub-Saharan Africa starting in the 1970s. In the Nineteen Nineties, he and colleagues examined how efficient chloroquine was in treating uncomplicated instances of malaria in rural Mali.

The root explanation for the resistance lay in a gene—not one in people however in the parasite’s DNA. Between 1996 and 2001, he labored as a visiting fellow with scientists at the National Institutes of Health (NIH) to establish a mutation in one among the parasite’s genes, a piece of DNA that codes for the protein Plasmodium falciparum chloroquine-resistant transporter, or PfCRT. The NIH crew discovered that the mutated protein stopped chloroquine from entering the parasite’s vacuole, the place the drug would in any other case kill the bug (Mol. Cell 2000, DOI: 10.1016/S1097-2765(05)00077-8).

Djimdé’s team then validated the mutation in the field in Mali, treating malaria sufferers with chloroquine and screening surviving parasites for the mutation (N. Engl. J. Med. 2001, DOI: 10.1056/NEJM200101253440403). Every resistant parasite carried it; each vulnerable one didn’t. “That was really the first validation of this point mutation in the field,” Djimdé says.

The group then developed an assay that required solely a dried blood spot on filter paper—no chilly chain or specialist tools wanted—and that could possibly be mailed like a traditional letter. The mutated gene turned the most generally used molecular instrument for monitoring chloroquine resistance globally.

The strategy of taking a fancy scientific discovering and making it work in the subject with minimal sources is what Djimdé brings to the UN advisory board, the place he argues that scientific improvements have to be judged by whether or not they can attain the individuals who want them most.

By the early 2000s, giant worldwide genomics consortia had been producing population-level knowledge on P. falciparum from throughout the world. A conclusion saved surfacing: African parasite populations confirmed low genetic variety. Compared with parasites from Asia or Latin America, African parasites appeared uniform. In the language of these public well being conferences, they had been the destructive management—scientifically uninteresting.

“We used to attend these meetings and think, That is not the full story. We knew that malaria behaved differently in different parts of the continent,” Djimdé says. “And we knew that must have been driven by genetic differences.”

In 2013, Djimdé and a gaggle of different African scientists formally launched the Plasmodium Diversity Network Africa, now referred to as the Pathogen Genomic Diversity Network Africa. The group finally assembled and analyzed parasite genes—all collected from the subject—from 15 African nations.

The outcomes overturned the consensus. Parasites from southern, central, jap, and western Africa had been all genetically distinct from one another. “It completely changed the way the field thought about and studied African parasites,” Djimdé says.

He needed to create a completely Africa-led analysis community simply to ask the proper questions, one thing Djimdé says informs his outlook as he begins work with the UN. Science governance, he argues, has the similar drawback genomics had: the frameworks are constructed with out African enter, and the blind spots comply with.

While constructing the community, Djimdé turned concerned in one among the most consequential issues in malaria drug growth. Pyramax, a mix drug, had proven sturdy efficacy even towards resistant strains of malaria, however early trials flagged liver toxicity instances. As a part of its approval of Pyramax in 2012, the European Medicines Agency restricted it to a single lifetime dose, pending extra knowledge.

For a continent the place kids endure a number of malaria episodes per 12 months, that was successfully a disqualification. “A drug that you can only use once in a lifetime is not a drug for Africa,” Djimdé says.

Between 2011 and 2016, his crew tracked sufferers throughout repeated infections, working with a West African medical trials community, Pyramax’s South Korean codeveloper, and the nonprofit and drug codeveloper Medicines for Malaria Venture. Each affected person was adopted for two years, a novel design at the time.

After monitoring greater than 14,000 malaria episodes, the researchers showed that Pyramax was both safe and effective with repeated use (Lancet 2018, DOI: 10.1016/S0140-6736(18)30291-5). The drug is now registered in greater than 20 nations throughout sub-Saharan Africa.

This kind of collaboration is an instance of what’s potential, Djimdé says. “When you match our local, life-driven perspective with the technology and know-how of our Northern colleagues, you find more useful solutions.”

Scovian Lillian is a contract science journalist based mostly in Kenya who covers well being, science, and schooling, amongst different subjects. A model of this story first appeared in ACS Central Science: cenm.ag/djimde.